NASDAQ$ONC
BeiGene Ltd-ADR · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
BeiGene's financial performance was marked by substantial revenue growth, driven by BRUKINSA sales, and a reduction in GAAP loss, alongside continued progress in R&D and pipeline expansion.
BeiGene reported a strong third quarter in 2024, achieving $1 billion in total revenue, driven by BRUKINSA sales. The company also reduced its GAAP loss and achieved its second consecutive quarter of positive non-GAAP operating income. They are expanding their oncology pipeline and global reach.
- Total revenue reached $1 billion, driven by BRUKINSA sales.
- BRUKINSA U.S. sales totaled $504 million, representing 87% growth year-over-year.
- BRUKINSA Europe sales totaled $97 million, representing 217% growth year-over-year.
- Four new molecular entities (NMEs) entered the clinic this quarter, with eight year-to-date.
Headline financials
Revenue & EPS history
BeiGene · Revenue · Quarterly
$1B
Revenue by segment
BeiGene · $211M total across 1 segment · Q1 2023
- BRUKINSA$211M+102.7%100.0%
Forward guidance
The company focuses on expanding TEVIMBRA's reach, advancing its pipeline, and improving access to medicines.
Tailwinds
- Expanding access to TEVIMBRA for patients worldwide.
- Building global commercial capabilities to support the pipeline.
- Laying the foundation for future franchises in breast, lung, and gastrointestinal cancers.
- Advancing preclinical programs into the clinic.
- Early clinical programs are progressing into late stage.
Headwinds
- Clinical results for drug candidates may not support further development or marketing approval.
- Actions of regulatory agencies may affect the initiation, timing, and progress of clinical trials and marketing approval.
- Reliance on third parties to conduct drug development, manufacturing, commercialization, and other services.
- Limited experience in obtaining regulatory approvals and commercializing pharmaceutical products.
- Ability to obtain additional funding for operations and to complete the development of drug candidates and achieve and maintain profitability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.1%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-2.0%
Avg return
30 days after
40%
16 / 40 earnings
Positive
+15.9%
Q4 2023
Best reaction
-9.6%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | +4.3% | -9.4% | |
| Q4 2025 | -8.5% | -15.7% | -19.6% | |
| Q3 2025 | +3.4% | +6.9% | +0.5% | |
| Q1 2025 | -3.9% | -3.5% | +5.8% | |
| Q4 2024 | +7.5% | -0.7% | +3.2% | |
| Q3 2024 | +1.4% | -4.5% | +1.4% | |
| Q2 2024 | +6.8% | +10.9% | +11.7% | |
| Q1 2024 | -2.0% | -2.2% | -4.9% | |
| Q4 2023 | +15.9% | +6.4% | -0.0% | |
| Q3 2023 | -0.5% | +0.7% | -12.6% | |
| Q2 2023 | -0.3% | -9.2% | +1.2% | |
| Q1 2023 | -5.7% | -7.3% | -14.2% | |
| Q4 2022 | +4.2% | +11.9% | +2.9% | |
| Q3 2022 | -0.2% | +7.3% | +4.2% | |
| Q2 2022 | +14.6% | +16.4% | -1.7% | |
| Q1 2022 | -9.6% | -11.9% | -12.9% | |
| Q4 2021 | -2.5% | -0.8% | -10.8% | |
| Q3 2021 | -2.3% | -1.1% | -15.9% | |
| Q2 2021 | -6.3% | -8.1% | -2.0% | |
| Q1 2021 | +2.2% | +5.4% | +15.7% | |
| Q4 2020 | -4.4% | -8.5% | -3.0% | |
| Q3 2020 | -3.6% | -7.2% | -26.8% | |
| Q2 2020 | -2.9% | -7.7% | +5.8% | |
| Q1 2020 | +1.0% | +6.0% | +9.6% | |
| Q4 2019 | -2.3% | -3.2% | -21.8% | |
| Q3 2019 | +2.9% | +3.4% | -6.5% | |
| Q2 2019 | +1.6% | +3.9% | -7.8% | |
| Q1 2019 | +14.2% | +13.6% | +4.3% | |
| Q4 2018 | -2.1% | +8.4% | -5.7% | |
| Q3 2018 | +1.4% | -11.2% | +10.4% | |
| Q2 2018 | -3.7% | -4.4% | -4.7% | |
| Q1 2018 | -5.2% | +4.3% | +20.9% | |
| Q4 2017 | -4.8% | +0.3% | +11.3% | |
| Q3 2017 | -5.5% | -0.0% | +10.4% | |
| Q2 2017 | -7.3% | -9.0% | -7.4% | |
| Q1 2017 | -1.3% | +0.7% | +3.9% | |
| Q4 2016 | -2.8% | -4.1% | -3.1% | |
| Q3 2016 | -4.7% | +7.4% | -19.5% | |
| Q2 2016 | +0.8% | +6.0% | +11.0% | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro